James Quigley
Stock Analyst at Goldman Sachs
(1.13)
# 3,790
Out of 5,090 analysts
24
Total ratings
40%
Success rate
-2.31%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Maintains: Buy | $60 → $54 | $47.86 | +12.83% | 1 | Nov 28, 2025 | |
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $132.16 | -10.71% | 2 | Sep 12, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $66.62 | +18.58% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $49.53 | +31.23% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.85 | +18.64% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $31.59 | +26.62% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.12 | +412.82% | 3 | Jun 23, 2023 |
Novo Nordisk
Nov 28, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $47.86
Upside: +12.83%
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $132.16
Upside: -10.71%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $66.62
Upside: +18.58%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $49.53
Upside: +31.23%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.85
Upside: +18.64%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $31.59
Upside: +26.62%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.12
Upside: +412.82%